Amylin Pharmaceuticals News

Illumina said its board has approved a plan to buy back up to $100 million of the San Diego company's stock.

Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks.

Investment professionals pick their favorite stock. We call it Love Only One, a contest in which we dare 17 financial pros to try to beat the S&P 500 by picking one stock each.

The latest estimates peg the number of people in the United States with diabetes at more than 24 million or almost 8 percent of the nation's total population.

Seeing shades of blue? On November 14, the whole globe will be seeing them, too.

For all the debate about possible reform to the U.S. medical system, it is easy to forget that the majority of major innovations in drugs and medical devices come from America.

The San Diego life sciences community is closely watching the discussions in Washington, D.C., regarding health care and insurance.

Amylin Pharmaceuticals is roaring back from a four-month low today after signing a marketing deal with Japan's Takeda Pharmaceutical.

SAN DIEGO Japanese drug maker Takeda Pharmaceutical Co. is banking on a U.S. pharmaceutical companya s obesity pipeline.

The FDA has approved revisions to the prescribing information for the injectable diabetes medication exenatide and the oral diabetes drug sitagliptin phosphate because of concerns about, respectively, renal problems and pancreatitis, which could be caused by the medications.

Amylin Pharmaceuticals and Takeda Pharmaceutical entered into a drug-development pact for the treatment of obesity and related indications.

Amylin Pharmaceuticals Inc. got a double dose of good news Monday, signing a $1 billion-plus deal to co-develop obesity compounds with Japanese partner Takeda Pharmaceutical Co.

Takeda Pharmaceutical Co. , maker of the worlda s best-selling diabetes drug, agreed to pay as much as $1 billion to Amylin Pharmaceuticals Inc.

Amylin Pharmaceuticals And Eli Lilly And Company Statement On FDA's BYETTA Injection Update Main Category: Urology / Nephrology Also Included In: Diabetes ; Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 03 Nov 2009 - 1:00 PST Amylin Pharmaceuticals, Inc., and Eli Lilly and Company issued the following statement ...

Investors are waiting for big obesity drug marketing deals from Vivus , Arena Pharmaceuticals and Orexigen Therapeutics , yet the first pact signed Sunday night comes from Amylin Pharmaceuticals ?!?! It's actually not that much of a surprise.

Drug stocks advanced in early trading Monday, as shares of Human Genome Sciences leaped on the release of more positive Phase III clinical data for its new lupus drug Benlysta.

Amylin Pharmaceuticals Inc. says it could potentially receive more than $1 billion from a partnership with Japan 's Takeda Pharmaceutical Co.

Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today announced that the U.S. Food and Drug Administration has approved an expanded indication for BYETTA injection.

Peter Sims, co-author of the best-selling business book "True North" and the forthcoming book "Little Bets" will provide the keynote for the BioWest 2009 Conference and Expo.